Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.
Whatever the consensus opinion may be, our team at StockStory cuts through the noise by conducting independent analysis to determine a company’s long-term prospects. That said, here are three stocks facing legitimate challenges and some alternatives worth exploring instead.
PepsiCo (PEP)
Consensus Price Target: $172 (9% implied return)
With a history that goes back more than a century, PepsiCo (NASDAQ:PEP) is a household name in food and beverages today and best known for its flagship soda.
Why Are We Wary of PEP?
- Falling unit sales over the past two years imply it may need to invest in product improvements to get back on track
- Anticipated sales growth of 4.3% for the next year implies demand will be shaky
- Day-to-day expenses have swelled relative to revenue over the last year as its operating margin fell by 1.2 percentage points
PepsiCo is trading at $157.80 per share, or 18x forward P/E. Read our free research report to see why you should think twice about including PEP in your portfolio.
Dover (DOV)
Consensus Price Target: $248.63 (9.4% implied return)
A company that manufactured critical equipment for the United States military during World War II, Dover (NYSE:DOV) manufactures engineered components and specialized equipment for numerous industries.
Why Does DOV Give Us Pause?
- Organic revenue growth fell short of our benchmarks over the past two years and implies it may need to improve its products, pricing, or go-to-market strategy
- Earnings growth over the last two years fell short of the peer group average as its EPS only increased by 5.8% annually
- Shrinking returns on capital suggest that increasing competition is eating into the company’s profitability
Dover’s stock price of $227.26 implies a valuation ratio of 3.5x forward price-to-sales. Dive into our free research report to see why there are better opportunities than DOV.
Teleflex (TFX)
Consensus Price Target: $132.78 (9% implied return)
With a portfolio spanning from vascular access catheters to minimally invasive surgical tools, Teleflex (NYSE:TFX) designs, manufactures, and supplies single-use medical devices used in critical care and surgical procedures across hospitals worldwide.
Why Do We Steer Clear of TFX?
- Annual sales declines of 18.3% for the past two years show its products and services struggled to connect with the market during this cycle
- Constant currency revenue growth has disappointed over the past two years and shows demand was soft
- Capital intensity has ramped up over the last five years as its free cash flow margin decreased by 20.6 percentage points
At $121.82 per share, Teleflex trades at 18.1x forward P/E. Check out our free in-depth research report to learn more about why TFX doesn’t pass our bar.
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.